In 2023, based on advances in the understanding of the pathological and molecular features of endometrial carcinoma, an updated International Federation of Gynaecology and Obstetrics (FIGO) staging system was published, aiming to better define prognostic groups and identify relevant treatment subgroups by including factors reflecting tumour biology (histological subtypes, lymphovascular space invasion, and molecular classification) alongside refinements of anatomical factors (peritoneal carcinomatosis and lymph node metastasis). As part of its mission to improve the quality of care for people with gynaecological cancers, the European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) updated the ESGO-ESTRO-ESP evidence-based guidelines published in 2021 by incorporating this revised FIGO staging and the large body of new evidence addressing the management of endometrial carcinoma. The development process of these guidelines was based on a systematic literature review and critical appraisal process involving an international multidisciplinary development group consisting of 30 experts from relevant disciplines (gynaecological oncology, radiation oncology, medical oncology, and pathology). A patient representative was also included. Before publication, the guidelines were reviewed by 225 independent international practitioners in cancer care delivery and three patient representatives from Asia, Europe, North Africa, North America, the Middle East, and South America to ensure a global perspective. These guidelines comprehensively cover diagnosis, management, follow-up, and patient education. Management includes surgical and adjuvant therapy according to the stage of the disease, and metastatic and recurrent disease. The management algorithms and the principles of radiotherapy and pathological evaluation are also defined.

Department of Biomedical Sciences Humanitas University Pieve Emanuele and Humanitas San Pio 10 Milan Italy

Department of Gynaecologic Oncology Leuven Cancer Institute University Hospitals Leuven Leuven Belgium

Department of Gynaecology Obstetrics and Neonatology General University Hospital Prague 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Gynaecology Oncology The Royal Marsden National Health Service Foundation Trust London UK

Department of Gynecological Surgery Gustave Roussy Cancer Campus Villejuif France; Université Paris Saclay Paris France

Department of Gynecology and Gynecological Oncology Medical University of Vienna Vienna Austria

Department of Gynecology and Obstetrics Technische Universität Dresden Dresden Germany

Department of Gynecology with Center for Oncological Surgery Charite Universitätsmedizin Berlin Berlin Germany

Department of Medical Oncology Amsterdam University Medical Centers Amsterdam Netherlands

Department of Obstetrics and Gynecology Medical University Innsbruck Innsbruck Austria

Department of Oncology Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

Department of Oncology University College London Cancer Institute University College London London UK

Department of Pathology Hospital Graz 2 Medical University of Graz Graz Austria; Johannes Kepler University Linz Austria

Department of Pathology Hospital Universitari Arnau de Vilanova Lleida Spain

Department of Pathology Hospital Universitari Arnau de Vilanova Lleida Spain; Department of Pathology Hospital Universitari de Bellvitge Barcelona Spain

Department of Pathology Leiden University Medical Center Leiden Netherlands

Department of Radiation Oncology Gustave Roussy Cancer Campus Villejuif France

Department of Radiation Oncology Leiden University Medical Center Leiden Netherlands

Department of Radiation Oncology Medical University of Vienna Vienna Austria

Department of Radiotherapy Erasmus MC Cancer Institute Rotterdam Netherlands

Department of Surgery and Cancer Faculty of Medicine Imperial College London London UK

Gynecologic Oncology Unit Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy

Gynecologic Program European Institute of Oncology IRCCS Milan Italy; Department of Medicine and Surgery University of Milan Bicocca Milan Italy

Gynecologic Service Department of Surgery Memorial Sloan Kettering Cancer Center New York NY USA

HaBait Shel Bar Israel Women's Cancer Association Tel Aviv Israel; Department of Public Health Faculty of Medicine Tel Aviv University Tel Aviv Israel

Histopathology and Molecular Diagnostics Azienda Ospedaliero Universitaria Careggi Florence Italy

Institut Bergonié Bordeaux France

Medical Oncology Department Cancer Center Clinica Universidad de Navarra Madrid Spain

Medical Oncology Service Vall d'Hebron Institute of Oncology Vall d'Hebron Barcelona Hospital Campus Barcelona Spain

Radiation Oncology Department Pitié Salpêtrière University Hospital Paris France

Radiation Oncology Unit Responsible Research Hospital Campobasso and Catholic University of Sacred Heart Rome Rome Italy

Lancet Oncol. 2025 Oct;26(10):e522. doi: 10.1016/S1470-2045(25)00560-1. PubMed

Citace poskytuje Crossref.org

Serum Levels of CA125 and HE4 as a Tool for Predicting Regional Lymph Node Metastatic Involvement in Endometrial Carcinoma